Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.

Detected 21/23 recurrences (91%): 5/5 T1, T2, and CIS (100%) and 10/12 Ta (83%); <1% false-negative tests.

Mol Oncol 2024;18(11):2684-2695.PubMed 38720532